508335566 01/16/2024

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT8382758

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
AXCELEAD DRUG DISCOVERY PARTNERS, INC.	09/13/2022

RECEIVING PARTY DATA

Name:	TAKEDA PHARMACEUTICAL COMPANY LIMITED	
Street Address:	1-1, DOSHOMACHI 4-CHOME, CHUO-KU	
City:	OSAKA-SHI, OSAKA	
State/Country:	JAPAN	
Postal Code:	541-0045	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	17754118

CORRESPONDENCE DATA

Fax Number: (202)408-4400

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 202-408-4000

Email: regional-desk@finnegan.com

Correspondent Name: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP

Address Line 1: 901 NEW YORK AVENUE, NW Address Line 4: WASHINGTON, D.C. 20001

ATTORNEY DOCKET NUMBER:	15496.0011-00000
NAME OF SUBMITTER:	KIMBERLY L. MASON
SIGNATURE:	/Kimberly L. Mason/
DATE SIGNED:	01/16/2024

Total Attachments: 2

source=PAT14178PCTUS01_Assignment_Axcelead_to_Takeda_15496_0011-00000#page1.tif source=PAT14178PCTUS01_Assignment_Axcelead_to_Takeda_15496_0011-00000#page2.tif

PATENT 508335566 REEL: 066136 FRAME: 0571

SOLE/JOINT INVENTION (Worldwide Rights) Attorney Docket No. 15496.0011-00000

ASSIGNMENT

WHEREAS **AXCELEAD DRUG DISCOVERY PARTNERS INC.**, a corporation of Japan, having an office and place of business at 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, Japan 251-0012 (hereinafter referred to as Assignor) owns the following invention by virtue of an assignment from inventors Hirotaka KAMITANI, Takaharu HIRAYAMA, Toshio TANAKA, Hiroshi BANNO, Nobuyuki TAKAKURA, Jinichi YONEMORI and Takuya FUJIMOTO:

HETEROCYCLIC COMPOUND AND USE THEREOF

for which a United States patent application was filed on March 24, 2022 (Application No. 17/754,118), a PCT Application was filed on September 25, 2020 (PCT/IB2020/000772) and a Japanese Application was filed on September 25, 2019 (JP 2019-174311) and;

WHEREAS, **TAKEDA PHARMACEUTICAL COMPANY LIMITED**, a corporation of Japan whose post office address is 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 Japan (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I, as Assignor, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, Assignor's entire right, title, and interest in and to this invention, and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States which may be granted thereon, and all reissues thereof, and all rights to claim priority in any foreign country on the basis of the above provisional application, as well as all rights to claim priority on the basis of this invention in any country, including any PCT application, and all Letters Patent which may be granted on this invention in any country, and all extensions, renewals, and reissues thereof. Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, Assignor HEREBY covenants that it has the full right to convey the interest assigned by this Assignment, and has not executed and will not execute any agreement in conflict with this Assignment;

AND, Assignor HEREBY further covenants and agrees that it will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to Assignor respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to obtain and/or perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand.

Signature:	shin	<u></u>	Iki	ma	
Printed Name: <u>Y</u>	oshinori	IKEU	RA		
Corporate Title:					
For: AXCELEAD D					_
Execution Date:					<u>, . </u>

SOLE/JOINT INVENTION (Worldwide Rights) Attorney Docket No. 15496.0011-00000

ACKNOWLEDGED BY:
Signature: Skuy Va
Printed Name:Takuya ABE
Corporate Title: IP Region Head, Japan
For: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Execution Date: Sentember 15 2022

RECORDED: 01/16/2024